HONOR Trial (Hypothalamic Obesity Neutralized On TAS2Rs)
ARD-101 is an investigational orally delivered small-molecule for the treatment of hyperphagia associated with Hypothalamic Obesity (HO). We believe ARD-101’s unique ability to induce gut-localized CCK and GLP-1 secretion could result in a reduction in hyperphagia for patients with Hypothalamic Obesity.
